Latest Biopharmaceutical Earnings News

Page 1 of 1

Neuren’s Royalties Climb as Profit Dips Amid Phase 3 Push and Dividend Debut

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.

Ada Torres

26 Aug 2026

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026